Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA and CIK cells in ovarian carcinoma
NCT02487693Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jul 2015
- Primary completion
- Jun 2038
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in ovarian carcinoma, sponsored by Changzhou First People's Hospital. Started Jul 2015; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT02487693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487693.